Haisco Pharmaceutical Group's high P/E ratio is concerning due to its poor earnings forecast. The inflated P/E from recent momentum may not be sustainable, posing a risk to shareholders and potential investors.

Haisco Pharmaceutical Group's slower EPS growth compared to its share price growth suggests future earnings growth is key for potential investors. The company's high P/E ratio indicates market optimism.

Analysts anticipate growth in future earnings despite mixed fundamentals, shrinking profits. Uncertainty for investors due to low ROE, lack of dividends.